Merck KGaA has announced plans to mothball its active pharmaceutical ingredient facility in Ireland by the end of 2028 as part of a broader global restructuring effort.

The company cited efficiency optimization and portfolio alignment as key reasons for the closure.

Local officials say they are working with the firm to support affected employees and attract new investment to the region’s biotech sector.